Cubist Pharmaceuticals (CBST) 71.00 $CBST
Cubist Pharmaceuticals Earnings Review: 20 Days after Announcement Shares Down 1.1% (CBST)
Comtex SmarTrend(R) - Mon May 12, 11:59AM CDT
Two weeks ago on April 22nd, 2014 Cubist Pharmaceuticals (NASDAQ:CBST) reported earnings and analysts, on average, expected earnings of $0.36 on sales of $285.1 million. The company actually reported EPS of $0.10 on sales of $261.2 million, missing EPS estimates by $0.26 and missing revenue estimates by $23.9 million. Shares of Cubist Pharmaceuticals have slipped from $68.20 to $67.47, representing a loss of 1.1%, since the company reported earnings 20 days ago.
Alnylam Up on Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:50AM CDT
Alnylam Pharma's (ALNY) shares were up ever since it announced its first quarter-results on May 8.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Cubist Presents Detailed Results from Positive Phase 3 Trials of Ceftolozane/Tazobactam at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Business Wire - Fri May 09, 6:01PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the first detailed results from positive pivotal Phase 3 clinical trials of its antibiotic candidate ceftolozane/tazobactam in development to treat serious infections including complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Results will be presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Barcelona May 10 - 13.
3 Biotech Stocks Making Big Moves Last Week
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Biotech investors have been taken on a roller coaster ride over the past few months as stratospheric gains in the fourth and first quarters have been realized to pay tax bills and rebalance to other industries. While Foolish investors should never...
New Drug Applications, Quarterly Results, and University Partnerships - Analyst Notes on Celgene, HCA, Thermo Fisher Scientific, Cubist and Agilent
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), HCA Holdings Inc. (NYSE: HCA), Thermo Fisher Scientific Inc. (NYSE: TMO), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1941-100free.
Top Gainers Technical Data -- Research on Wolverine World Wide, MagneGas, Sequenom, and Cubist Pharma
PR Newswire - Thu May 01, 3:22AM CDT
On Tuesday, April 29, 2014, the NASDAQ Composite ended at 4,103.54, up 0.72%, the Dow Jones Industrial Average advanced 0.53%, to finish the day at 16,535.37, and the S&P 500 closed at 1,878.33, up 0.48%. The session saw a positive impact from Financials, Information Technology, and Materials sectors along with a drag from Utilities and Consumer Staples sectors. A number of stocks saw large movements, including Wolverine World Wide Inc. (NYSE: WWW), MagneGas Corp. (NASDAQ: MNGA), Sequenom Inc. (NASDAQ: SQNM) and Cubist Pharmaceuticals Inc. (NASDAQ: CBST). Free technical research on WWW, MNGA, SQNM and CBST can be downloaded upon signing up at:
Cubist to Present New Antibiotics Pipeline Data at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Business Wire - Wed Apr 30, 9:07AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will present data from its late-stage antibiotics pipeline at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, May 10-13. Data highlighted will offer insights into Cubist's research and development programs, which focus on Gram-positive and Gram-negative bacteria that cause serious and complicated infections. Presentations will include the first detailed results from the pivotal Phase 3 clinical trials of the Company's investigational antibiotic ceftolozane/tazobactam being developed to treat complicated urinary tract infections and complicated intra-abdominal infections.
After Yesterday's Rally of 12.52% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 29, 5:02PM CDT
Cubist Pharmaceuticals (NASDAQ:CBST) traded in a range yesterday that spanned from a low of $64.77 to a high of $70.16. Yesterday, the shares gained 12.5%, which took the trading range above the 3-day high of $67.50 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Shares of CBST Down 15.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 28, 9:13AM CDT
SmarTrend identified a Downtrend for Cubist Pharmaceuticals (NASDAQ:CBST) on March 24th, 2014 at $73.60. In approximately 1 month, Cubist Pharmaceuticals has returned 15.61% as of today's recent price of $62.10.
Cubist Pharma Posts Weak Earnings on Soft Cubicin Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 10:30AM CDT
Cubist Pharma missed both on earnings and revenues.
Cubist and Cambridge Science Festival Announce 2014 Germ Challenge Science Contest Winners
Business Wire - Wed Apr 23, 7:30AM CDT
Cambridge Science Festival and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the winners of the 2014 Germ Challenge, a contest designed to engage young people in science by inviting them to develop educational and creative videos that demonstrate their knowledge of germs and ability to communicate scientific concepts in a way that appeals to the general public.
Cubist Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Tue Apr 22, 3:00PM CDT
--Non-GAAP Adjusted Operating Income of $18.8 Million; GAAP Operating Income of $28.3 Million
This is the 1 Thing AstraZeneca Should Do to Improve Shareholder Value
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 1:05PM CDT
It's only Tuesday and this has already been an exciting week in the health-care sector. I'm speaking of the news this weekend that pharma giant Pfizer reportedly considered making a $101 billion bid for U.K.-based rival AstraZeneca , a 27%...
Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Cubist Announces Submission of New Drug Application for Investigational Antibiotic Ceftolozane/tazobactam
Business Wire - Mon Apr 21, 7:31AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of its investigational antibiotic ceftolozane/tazobactam for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI).
Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of One Lot of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter
Business Wire - Fri Apr 18, 10:59AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling one lot of CUBICIN(R) (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles, found in a single vial from this lot, produced by a contract manufacturer.
Cubist to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Business Wire - Tue Apr 15, 7:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its first quarter financial results, business activities, and financial outlook.
Cubist Pharmaceuticals Earnings Review: 20 Days after Announcement Shares Down 1.1% (CBST)
Comtex SmarTrend(R) - Mon May 12, 11:59AM CDT
Two weeks ago on April 22nd, 2014 Cubist Pharmaceuticals (NASDAQ:CBST) reported earnings and analysts, on average, expected earnings of $0.36 on sales of $285.1 million. The company actually reported EPS of $0.10 on sales of $261.2 million, missing EPS estimates by $0.26 and missing revenue estimates by $23.9 million. Shares of Cubist Pharmaceuticals have slipped from $68.20 to $67.47, representing a loss of 1.1%, since the company reported earnings 20 days ago.
Alnylam Up on Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:50AM CDT
Alnylam Pharma's (ALNY) shares were up ever since it announced its first quarter-results on May 8.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Cubist Presents Detailed Results from Positive Phase 3 Trials of Ceftolozane/Tazobactam at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Business Wire - Fri May 09, 6:01PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the first detailed results from positive pivotal Phase 3 clinical trials of its antibiotic candidate ceftolozane/tazobactam in development to treat serious infections including complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Results will be presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Barcelona May 10 - 13.
3 Biotech Stocks Making Big Moves Last Week
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Biotech investors have been taken on a roller coaster ride over the past few months as stratospheric gains in the fourth and first quarters have been realized to pay tax bills and rebalance to other industries. While Foolish investors should never...
New Drug Applications, Quarterly Results, and University Partnerships - Analyst Notes on Celgene, HCA, Thermo Fisher Scientific, Cubist and Agilent
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), HCA Holdings Inc. (NYSE: HCA), Thermo Fisher Scientific Inc. (NYSE: TMO), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1941-100free.
Top Gainers Technical Data -- Research on Wolverine World Wide, MagneGas, Sequenom, and Cubist Pharma
PR Newswire - Thu May 01, 3:22AM CDT
On Tuesday, April 29, 2014, the NASDAQ Composite ended at 4,103.54, up 0.72%, the Dow Jones Industrial Average advanced 0.53%, to finish the day at 16,535.37, and the S&P 500 closed at 1,878.33, up 0.48%. The session saw a positive impact from Financials, Information Technology, and Materials sectors along with a drag from Utilities and Consumer Staples sectors. A number of stocks saw large movements, including Wolverine World Wide Inc. (NYSE: WWW), MagneGas Corp. (NASDAQ: MNGA), Sequenom Inc. (NASDAQ: SQNM) and Cubist Pharmaceuticals Inc. (NASDAQ: CBST). Free technical research on WWW, MNGA, SQNM and CBST can be downloaded upon signing up at:
Cubist to Present New Antibiotics Pipeline Data at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Business Wire - Wed Apr 30, 9:07AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will present data from its late-stage antibiotics pipeline at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, May 10-13. Data highlighted will offer insights into Cubist's research and development programs, which focus on Gram-positive and Gram-negative bacteria that cause serious and complicated infections. Presentations will include the first detailed results from the pivotal Phase 3 clinical trials of the Company's investigational antibiotic ceftolozane/tazobactam being developed to treat complicated urinary tract infections and complicated intra-abdominal infections.
After Yesterday's Rally of 12.52% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 29, 5:02PM CDT
Cubist Pharmaceuticals (NASDAQ:CBST) traded in a range yesterday that spanned from a low of $64.77 to a high of $70.16. Yesterday, the shares gained 12.5%, which took the trading range above the 3-day high of $67.50 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Shares of CBST Down 15.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 28, 9:13AM CDT
SmarTrend identified a Downtrend for Cubist Pharmaceuticals (NASDAQ:CBST) on March 24th, 2014 at $73.60. In approximately 1 month, Cubist Pharmaceuticals has returned 15.61% as of today's recent price of $62.10.
Cubist Pharma Posts Weak Earnings on Soft Cubicin Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 10:30AM CDT
Cubist Pharma missed both on earnings and revenues.
Cubist and Cambridge Science Festival Announce 2014 Germ Challenge Science Contest Winners
Business Wire - Wed Apr 23, 7:30AM CDT
Cambridge Science Festival and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the winners of the 2014 Germ Challenge, a contest designed to engage young people in science by inviting them to develop educational and creative videos that demonstrate their knowledge of germs and ability to communicate scientific concepts in a way that appeals to the general public.
Cubist Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Tue Apr 22, 3:00PM CDT
--Non-GAAP Adjusted Operating Income of $18.8 Million; GAAP Operating Income of $28.3 Million
This is the 1 Thing AstraZeneca Should Do to Improve Shareholder Value
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 1:05PM CDT
It's only Tuesday and this has already been an exciting week in the health-care sector. I'm speaking of the news this weekend that pharma giant Pfizer reportedly considered making a $101 billion bid for U.K.-based rival AstraZeneca , a 27%...
Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Cubist Announces Submission of New Drug Application for Investigational Antibiotic Ceftolozane/tazobactam
Business Wire - Mon Apr 21, 7:31AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of its investigational antibiotic ceftolozane/tazobactam for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI).
Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of One Lot of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter
Business Wire - Fri Apr 18, 10:59AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling one lot of CUBICIN(R) (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles, found in a single vial from this lot, produced by a contract manufacturer.
Cubist to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Business Wire - Tue Apr 15, 7:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its first quarter financial results, business activities, and financial outlook.
